Lawrence Fong

I want to jump in on sharing some of my highlights from American Society of Clinical Oncology (ASCO) - Melody K Schiaffino, PhD, MPH UC San Diego Health - Moores Cancer Center Cancer and Aging Research Group (CARG) OncoDaily #ASCO24 #Cancer #OncoDaily #Oncology #UCSanDiego #SchoolOfMedicine

13

Great study profiling your immune status and response to immune checkpoint inhibition.

7

Phase IIb data for Auxora in an acute pancreatitis subpopulation is expected to set up the CRAC channel inhibitor for Phase III in that indication while suggesting positive read-through for AKI. https://lnkd.in/eDzU4m8e?

1

We are excited to share our latest paper in iScience describing the complex role of dysregulated innate/inflammatory signaling in the progression of MDS to AML with RUNX1 mutations. https://lnkd.in/gQdHy_ze Congrats to lead author Laura Barreyro for spearheading the project. We are grateful to the insightful reviewers, our collaborators, and for support from CancerFreeKids, Leukemia and Lymphoma Society, NIH, UCCC, and CCHMC. Our study shows loss of miR146a - a commonly deleted gene in MDS - and mutant RUNX1 initially induce MDS and then progress to AML. At the AML stage, RUNX1 mutant rewires inflammatory pathways. Inhibiting immune signaling suppresses leukemic cells, highlighting the role of immune dysregulation at initiation and later stages of AML. These results provide evidence that dysregulation of innate immune and inflammatory signaling is essential for propagating pre-leukemic cells and contributes to the progression of AML. #LeukemiaResearch #AML #MDS #Inflammation #miR146a #RUNX1

114

3 Comments

New Insights into Alzheimer's Disease from Mount Sinai Researchers Our latest study, published in Nature Neuroscience, explores the role of reactive #astrocytes and the plexin-B1 protein in Alzheimer's pathophysiology. Key Findings: Reactive Astrocytes: Activated in response to brain injury or disease, these cells play a crucial role in regulating the spacing around amyloid plaques, impacting how other brain cells interact with and clear these deposits. Plexin-B1 Protein: The study highlights the manipulation of this protein to enhance amyloid plaque clearance, offering new insights into potential therapeutic strategies. Gene Network Models: Validation of multiscale gene network models advances our understanding of Alzheimer's and underscores the potential of targeted therapies. Dr. Bin Zhang, Willard T.C. Johnson Research Professor of Neurogenetics, notes, “Our study significantly enhances the understanding of Alzheimer's disease and supports the development of novel therapeutics.” Dr. Roland Friedel, Associate Professor of Neuroscience and Neurosurgery, states, “Our findings suggest a promising avenue for developing treatments that improve cellular interactions with amyloid plaques.” Dr. Hongyan Zou, Professor of Neurosurgery and Neuroscience, adds, “This research emphasizes the importance of cellular interactions in the development of neurodegenerative disease treatments.” This research was supported by the NIH National Institute on Aging (NIA) and is part of the AMP-AD program, which aims to accelerate the discovery and development of new treatments for #Alzheimers disease. 🔗 Learn More: https://lnkd.in/eZHHk99S The Friedman Brain Institute Icahn School of Medicine at Mount Sinai #AlzheimersResearch #NetworkModeling #amyloidplaques

9

We've dosed the first patient with cholangiocarcinoma, or bile tract cancer, in the intravenous (IV) infusion combination arm of our Phase 1 onCARlytics trial at the City of Hope in California. This trial marks a world-first by combining a CD19-expressing oncolytic virus with a CD19-targeting drug, blinatumomab, to treat advanced solid tumours. The trial aims to recruit 40-45 patients with advanced solid cancers that have spread and assesses both intratumoural and intravenous administration routes. Initial data from the combination arm is expected in Q4 2024, focusing on converting "targetless" tumours to CD19-expressing targets for effective treatment. Managing Director & CEO Leslie Chong said: “We are pleased to enroll the first IV combination patient and further advance our OASIS trial, which combines our CD19 oncolytic virus with the already approved and marketed CD19 bispecific in patients with advanced solid cancers. While CD19 has been a powerful target for blood cancers, no such targets currently exist for solid cancers. We aspire to change that with onCARlytics, which causes cancers to display CD19 on their cell surface so that an approved CD19 therapeutics can target and kill the cancer. If successful, onCARlytics could open up 90 percent of the market as CD19 products are only approved in blood cancer and provide a new treatment option for patients with solid tumors.” Read the full ASX Announcement here: https://lnkd.in/gtqv5FC8 #Imugene #IMU #onCARlytics #OASIStrial #Immunotherapy #CancerResearch #ClinicalTrial #CD19Therapy #BileTractCancer #OncolyticVirotherapy #cholangiocarcinoma

91

2 Comments

In this episode of #LungCancerConsidered, host Dr. Stephen Liu discusses KRAS mutant #NSCLC, focusing on non-G12C mutations. KRAS mutations are very common in #lungcancer and while there are now multiple approved and active KRAS inhibitors, they are specifically for the G12C mutation. Newer strategies are needed for other common mutations such as KRAS G12V and G12D and fortunately, new drugs are on the horizon. With guests Dr. Rajwanth R. Veluswamy, from Mount Sinai and Dr. Mariana Brandao, from the University of Brussels. Listen: https://bit.ly/24KRASG12C #LCSM

12

While #ASCO24 is at an end, it was great following all of it on social media. If you were at ASCO and interested in potential collaborations with the journal Technology in Cancer Research & Treatment, please feel free to reach out. Thanks for sharing OncoDaily! #cancer #oncology #cancerresearch #oncodaily

5

Phase II of a new Lp(a) inhibitor ☀️

2

📢New article alert from the Journal of Comparative Effectiveness Research:   Title: Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US   New research from Hernandez et al. compares adverse event management costs for fruquintinib, regorafenib, trifluridine/tipiracil (T/T), and T/T+bevacizumab for metastatic colorectal cancer patients previously treated with at least two prior lines of therapy. The article provides valuable insights for treatment, formulary and pathway decisions.   Authors: Victoria Federico Paly, N. Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan P. & Luis Hernandez Takeda Oncology, MD Anderson Cancer Center, Mayo Clinic   #Oncology #HealthEconomics #mCRC #PharmaResearch #OpenAccess   Link in the comments!

22

2 Comments

Numerous studies conducted by Dana-Farber researchers show promising results for patients with endometrial, lung, breast, prostate, and colorectal cancers. The results of these studies, along with dozens of others led by Dana-Farber faculty, were presented at this year’s American Association for Cancer Research (AACR) Annual Meeting last month in California.   Notable research from Dana-Farber researchers included: Novel ADC and Immunotherapy Combo Shows Promise in Endometrial Cancer Subtype  Rebecca Porter, MD, PhD, a medical oncologist in the Gynecological Oncology Program of the Susan F. Smith Center for Women’s Cancers, presented results of a small, investigator-initiated phase 2 study of a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor. Blood Test May Identify Patients with Non-Small Cell Lung Cancer Subtype Who Can Benefit from Combination Therapy  Pasi Jänne, MD, PhD, senior vice president for Translational Medicine, presented an update to his practice-changing FLAURA2 clinical trial published last year, revealing that patients with non-small cell lung cancer (NSCLC) marked by a mutation in the EGFR gene fared significantly better when treated with the drug osimertinib plus platinum-based chemotherapy than with osimertinib alone. Exercise Program Can Improve Heart Function in Cancer Survivors  Cami Christopher, MPH, a research scientist in the Department of Medical Oncology, Population Sciences, presented findings suggesting that a moderate to vigorous aerobic and resistance exercise program can improve a key aspect of heart function in survivors of breast, prostate, and colorectal cancer. Study Provides First Large-Scale Look at Genetic Architecture of Prostate Cancer in Sub-Saharan Africa  Timothy Rebbeck, PhD, the Vincent L. Gregory Professor of Cancer Prevention, led the first large-scale genomic analysis of prostate cancer in sub-Saharan Africa which revealed that the genetic architecture of the disease – its basic underpinnings in abnormalities in DNA – is unique to Africa and varies across the continent. In addition, the AACR recognized Rebbeck, Christopher D.M. Fletcher, MD, FRCPath, and Gordon J. Freeman, PhD, with 2024 Scientific Achievement Awards during the Annual Meeting.  More: https://lnkd.in/etk8fwUp

58

1 Comment

❗Interested in submitting to the journal Technology in Cancer Research & Treatment? Check out the Aims and Scope below. https://lnkd.in/gMPx7e83 Additional info: - CiteScore 4.4 (Q2)/Impact Factor 2.7 (Q3) - Doube-anonymized peer review, avg. time to first decision under 60 days - Indexed in SCIE, PMC, PubMed: MEDLINE, Scopus, DOAJ - Gold open access, no page limits or page charges - Tiered Article Processing Charge (APC) pricing based on article types - Authors retain copyright under a Creative Commons License - Published articles accessible to anyone Sage #cancerdetection #cancerdiagnosis #cancertreatment #artificialintelligence #medicalimaging #biomarker #medphys #radonc #oncology #personalizedmedicine #pathology

8

Faeth Therapeutics CEO and Co-Founder Anand Parikh says the potential of Artificial Intelligence to accelerate medical discovery is immense, particularly within biology. Embracing AI in biology means tackling some of the most complex and variable aspects of science for the very first time. By focusing AI’s power on the untapped potential of the metabolic genome in cancer research, for example, we are not just making incremental improvements but are positioned to make quantum leaps in understanding, managing and treating cancer. By doing so, we are setting the stage for discoveries that could fundamentally alter our approach to health and disease, making biology the next great frontier for AI. Read Anand's full thoughts in Drug Discovery & Development: https://lnkd.in/gA3A9sgS

6

I'm thrilled to share our latest paper, the first to describe the neuroanatomic correlates of itching in patients with FTLD. Our study, conducted at UCSF Memory and Aging Center, highlights the higher prevalence of itching in frontotemporal lobar degeneration (FTLD) and identifies specific brain regions involved. This research underscores the potential of unexplained itching as an indicator of neurodegenerative processes. Link for the full article: https://lnkd.in/dqN-PxeJ

42

3 Comments

Listen in as Meagan Ryan, Senior Scientist, Biology, sheds light on the RAS- and RAF-driven cancers. They are notoriously difficult to treat clinically and, outside of BRAF Class I- and KRAS G12C-mutant cancers, have no approved targeted therapies. NST-628 is a pan-RAF-MEK non-degrader molecular glue that is positioned to make a broad impact in areas of unmet patient needs. You can read more about it here: https://lnkd.in/gBz-dmpH

50